AEterna Zentaris Inc. (USA)  

(Public, NASDAQ:AEZS)   Watch this stock  
Find more results for nasdaq: aezs
3.45
-0.04 (-1.15%)
Sep 23 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.45 - 3.51
52 week 2.60 - 15.70
Open 3.47
Vol / Avg. 0.00/86,159.00
Mkt cap 34.51M
P/E     -
Div/yield     -
EPS -9.24
Shares 9.94M
Beta 1.93
Inst. own 179%
Nov 3, 2016
Q3 2016 AEterna Zentaris Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Sep 12, 2016
AEterna Zentaris Inc at Rodman & Renshaw Global Investment Conference
Aug 10, 2016
Q2 2016 AEterna Zentaris Inc Earnings Call
Aug 9, 2016
Q2 2016 AEterna Zentaris Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -7300.00% -9216.15%
Operating margin -7483.33% -6400.73%
EBITD margin - -6338.16%
Return on average assets -69.31% -101.54%
Return on average equity -221.78% -278.28%
Employees 56 -
CDP Score - -

Address

1 Ville-Marie Pl Suite 2500
MONTREAL, QC H3B 1R1
Canada
+1-514-8474516 (Phone)
+1-418-9489191 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Aeterna Zentaris Inc. is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women's health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others. The Company's principal product candidates are Zoptrex (zoptarelin doxorubicin) and Macrilen (macimorelin) in oncology and endocrinology. The Company focuses on its product candidates Zoptrex and Macrilen, which are in Phase III clinical development, and on a luteinizing hormone-releasing hormone (LHRH)-disorazol Z conjugate (AEZS-138), which is in pre-clinical development in oncology and is available for partnering. The Company's direct and indirect subsidiaries include AEZS GmbH, Zentaris IVF GmbH and Aeterna Zentaris, Inc.

Officers and directors

David A. Dodd Chairman of the Board, President, Chief Executive Officer
Age: 65
Bio & Compensation  - Reuters
Dennis Turpin CA Chief Financial Officer, Senior Vice President
Bio & Compensation  - Reuters
Philip Allen Theodore Senior Vice President, Chief Administrative Officer, General Counsel
Age: 62
Bio & Compensation  - Reuters
Richard Sachse M.D. Ph.D. Senior Vice President, Chief Scientific Officer, Chief Medical Officer
Bio & Compensation  - Reuters
Jude Dinges Chief Commercial Officer, Senior Vice President
Bio & Compensation  - Reuters
Genevieve Lemaire Chief Accounting Officer, Vice President - Finance
Bio & Compensation  - Reuters
Michael Teifel Vice President - Non-Clinical Sciences
Bio & Compensation  - Reuters
Juergen H. L. Ernst Lead Independent Director
Age: 76
Bio & Compensation  - Reuters
Michael A. Cardiff Director
Bio & Compensation  - Reuters
Kenneth E. Newport CPA Director
Age: 49
Bio & Compensation  - Reuters